icon-folder.gif   Conference Reports for NATAP  
 
  Infectious Disease Societyof America (IDSA)
IDSA 49th Annual Meeting
October 20-23, 2011
Boston, MA
Back grey_arrow_rt.gif
 
 
 
Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Na´ve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study
 
 
  Reported by Jules Levin
Forty Ninth Infectious Disease Society of America Annual Meeting ·
Boston, Massachusetts ·
20-23 October

Roger Trinh1, Joseph Gathe2, Jacques Reynes3, Federico Pulido4, Ruth Soto-Malave5, Min Tian1, Linda Fredrick1, Thomas Podsadecki1, Michael Norton1, Angela Nilius1
1Abbott, Abbott Park, Illinois; 2Therapeutic Concepts, Houston, Texas; 3Department of Infectious and Tropical Diseases, Montpellier University Hospital, Montpellier, France; 4Unidad VIH. Hospital Universitario 12 de Octubre,
Universidad Complutense de Madrid, Madrid, Spain; 5University of Puerto Rico, School of Medicine, Infectious Diseases Section, San Juan, Puerto Rico and Innovative Care PSC, Bayamon, Puerto Rico

First-Line Darunavir/Raltegravir Riskier With Viral Load Above 100000

www.natap.org/2011/CROI/croi_107.htm


Mar 2, 2011 - People who began a first-line nucleoside-free regimen of darunavir/ritonavir plus raltegravir with a viral load above 100000 copies ran a higher ...

Results from a Single Arm Study of Darunavir/RitonavirPlus ...

www.natap.org/2011/CROI/croi_108.htm


Mar 2, 2011 - Results from a Single Arm Study of Darunavir/RitonavirPlus Raltegravir in Treatment-Na´ve HIV-1-Infected Patients (ACTG A5262). Reported by ...

Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus

www.natap.org/2011/HIV/090611_01.htm
-

Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262). Download the PDF ...

[PDF]

Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus

www.natap.org/.../Efficacy_of_a_Nucleoside_sparing_Regimen_of.9..
.

File Format: PDF/Adobe Acrobat
by B Taiwo - 2011 -
Objective: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination ... Keywords: antiretroviral therapy, darunavir, nucleoside-sparing, raltegravir ...

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif

HCV11.gif

HCV12.gif